Sanofi in Italia
In Italy, Sanofi is one of the leading pharmaceutical companies in terms of industrial presence and number of employees - over 2,000 employees, half of whom work in the industrial sector. Sanofi has three production plants in Italy - in Origgio (VA), Anagni (FR) and Scoppito (AQ), each with a specific specialisation and a strategic role for the Group.
We are an innovative, global health company, and we are driven by one purpose: to chase the miracle of science to improve people's lives. In our 50-year history, we have many scientific breakthroughs behind us in the service of patients. We developed the first treatments for many rare lysosomal storage diseases, as well as treatments for diabetes and cardiovascular disease that today represent the standard of care. Sanofi's commitment to public health has protected millions of people from flu every year for decades and helped virtually eradicate polio, while its vision of science has led to groundbreaking innovations in the treatment of inflammatory diseases. Present in some 100 countries around the world, with more than 100,000 employees, 70 industrial plants and 20 R&D centres, we strive to push the boundaries of science a little further every day.
Work with us
Working at Sanofi means being passionate about your work, aimed at meeting the health needs of patients around the world, building your professional future day by day.
Applications are selected by Sanofi.
Click on the following link to see job vacancies and student programmes worldwide.
Sanofi Studies
Clinical research
Sanofi's research unit in Italy coordinates the activities of the Southern European Cluster, which includes Greece and Cyprus, Israel, Bulgaria, Romania and Moldova, Croatia, Serbia, Slovenia, Albania, Bosnia Herzegovina and the Republic of North Macedonia.
The Anagni (FR) manufacturing plant
The Anagni plant, which is committed to reducing CO2 emissions by 67% over the period 2019-2025, has been transformed to accommodate the production of biotech drugs in liquid and injectable form that will enhance the production of vaccines, monoclonal antibodies and enzyme replacement therapies for rare diseases. In Anagni, moreover, thanks to funding from the IPCEI (Important Projects of Common European Interest) State Fund, Sanofi is developing a high-tech project to develop an innovative freeze-drying process.
The Origgio (VA) manufacturing plant
The Origgio plant is a biotechnology facility dedicated to the production of some key brands in the Consumer Healthcare range. By 2025, the plant has the ambition to double its production capacity.
In recent years, thanks to the Probiotikà project and new projects
supported by the MISE, it is involved in the industrial development of new probiotics, liquid forms and oral suspensions.
The Origgio site is also committed to reducing its environmental impact thanks to a photovoltaic plant with a capacity of 400 Kp that allows annual energy savings of 453,000 Kw.
The Scoppito (AQ) manufacturing plant
The Scoppito site has always been a strategic facility for the production and packaging of large-scale solid oral drugs. Between 2020 and 2022, Sanofi has invested almost €50 million to create a global centre of excellence in Scoppito for the development of innovative molecules from the Group's research pipeline. Small molecules that could revolutionise the approach to certain rare, neurological and autoimmune diseases will be industrialised here. The new Columbus high potency workshop is completely digitised and works there using augmented reality. On the environmental front, a programme is underway in Scoppito to reduce CO2 emissions by 43% over five years between 2021 and 2026.
Information letter
Sanofi is currently conducting a retrospective chart review study of patients with cold agglutinin disease (CAD) to better understand thrombotic events and mortality in CAD.
If you have not been in contact with the physician at your centre for some time, please select "See more" as you may be interested.